NEWS
LATEST
FULL LIST
-
Biofabricated Organ Support: miroliverELAP’s First Human Treatment for Acute Liver Failure
Overview On June 24, 2025, United Therapeutics Corporation (Nasdaq: UTHR) and Intermountain Health treated the first patient in a Phase 1 clinical trial of miroliverELAP®, an external liver support system that leverages a bioengineered porcine scaffold repopulated with human cells. This landmark event marks the world’s first human use of a bioengineered organ alternative designed…
-
Vivodyne Raises $40M to Scale AI and Robotics-Driven Human Tissue Platform for Drug Discovery
Funding Round and Expansion Vivodyne has secured $40 million in Series A funding to advance its human tissue-based drug development platform. The investment will support the expansion of its robotics and AI-powered preclinical testing infrastructure, including a new 23,000-square-foot automated lab at Genesis Marina in South San Francisco. The facility is designed to meet growing…
-
Vital3D Targets Pet Care Market as Strategic Entry Point to Bioprinted Human Organs
Commercial Focus Begins with Veterinary Wound Care Lithuanian startup Vital3D is positioning itself at the forefront of bioprinted organ development, with a projected timeline of 10 to 15 years for human applications. As a first step toward that goal, the company is entering the market with VitalHeal, a 3D-bioprinted wound patch for pets — beginning…
-
OrganOx Secures $160M in Private Financing to Accelerate Organ Perfusion Technology Expansion
Oxford, UK – May 8, 2025 — OrganOx Ltd. has completed the second closing of a $160 million private financing round, bringing in new strategic investors Intuitive Ventures and Terumo Ventures. The investment will support the company’s continued expansion of its metra® perfusion technology, which aims to improve transplant outcomes and organ availability globally. Technology…
-
Collagen-Based 3D Bioprinting Offers Fully Perfusable Gel Based Organ-On-Chips
A team of bioengineers at Carnegie Mellon University has unveiled a new tissue engineering platform. The study, published in Science Advances, introduces CHIPS (Collagen-based High-resolution Internally Perfusable Scaffolds), a new class of biological, perfusable 3D-printed tissue constructs, and VAPOR, a customizable perfusion bioreactor designed to support them. What’s the Technology? The platform uses an improved…
-
Quris Technologies Demonstrates Liver-Driven Brain Toxicity in New Multi-Organ Model
A recent study by Quris Technologies highlights how drug metabolism in the liver can significantly alter a compound’s neurotoxicity, providing new insights into limitations of traditional drug testing methods. Published in Biomedicine & Pharmacotherapy, the findings suggest a greater role for multi-organ, human-relevant testing platforms in preclinical development. Using a proprietary platform called BioAI, Quris…
-
VivoSim Labs Introduces NAMkind Platform for Human-Based Drug Testing Models
VivoSim Labs, a new initiative associated with Organovo, has launched a suite of services under the brand “NAMkind,” aimed at improving drug development through human-based predictive models. The company focuses on New Approach Methodologies (NAMs), which include both engineered human tissue systems and in silico modeling, to offer alternatives to traditional animal testing. VivoSim develops…
-
Cellino and Karis Bio Partner to Advance Personalized iPSC Therapies for Peripheral Artery Disease
Cellino, a Cambridge-based biotech innovator specializing in autonomous biomanufacturing, has announced a strategic partnership with Karis Bio, a South Korean leader in cell therapy, to drive forward a groundbreaking autologous induced pluripotent stem cell (iPSC)-derived therapy for cardiovascular disease. This collaboration not only marks Cellino’s expansion into the Asia-Pacific market but also represents a pivotal…
-
Vivodyne CEO Discusses FDA’s Move Away from Animal Testing and the Future of Humanized Drug Development
By Contract Pharma Staff Vivodyne, a pioneering biotech developing humanized drug testing platforms, stands positioned to capitalize as the FDA announces its initiative to phase out animal testing requirements for monoclonal antibodies (mAbs) and other drug therapies. With its fully automated platform that uses lab-grown human tissues and AI-driven analysis, Vivodyne is ready to push…
-
Organovo Rebrands as VivoSim Labs to Advance 3D Bioprinting Technology
Organovo Holdings, Inc. (Nasdaq: ONVO), a pioneer in 3D bioprinting technology, announced today that it will officially change its name to VivoSim Labs, Inc., marking a new chapter in the company’s mission to advance bioprinting innovations. The rebranding takes effect on April 24, 2025, when the company will begin trading under the new ticker symbol…
Subscribe
Enter your email below to receive updates.
The Business of Biofabrication 